drugset

drugset / Trial / NCT00794274

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274 ↗

Phase 2/3 Completed 15 enrolled University of Cincinnati Celgene Corporation · collab Medical University of South Carolina · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.

Timeline

Start: 2008-11
Primary completion: 2011-12
Completion: 2011-12

Publications

Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012 Feb;148(2):262-4. doi: 10.1001/archdermatol.2011.301. Epub 2011 Oct 17. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CC-100004	Unknown	20 mg	Oral

Indications